{
  "meta": {
    "title": "Antiviral_Agents_Herpes_Hiv_Influenza_Hbv_And_Hcv",
    "url": "https://brainandscalpel.vercel.app/antiviral-agents-herpes-hiv-influenza-hbv-and-hcv-a8747882.html",
    "scrapedAt": "2025-11-30T11:19:41.505Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Acyclovir, penciclovir, famciclovir</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Acyclovir, valacyclovir, famciclovir</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Valacyclovir, penciclovir, famciclovir</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Valacyclovir, famciclovir, lamivudine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 34-year-old male patient came to the OPD with the complaint of bilateral genital vesicles, fever, and itching. He is a known case of HIV and has been on ART for the last 4 years. So, he is diagnosed with genital HSV infection in HIV. There are three nucleoside analogues licensed for the treatment of HSV and VZV. Which of the following are three agents?</span></p>",
      "unique_key": "DT1176805",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176805,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Three oral nucleoside analogues are licensed for the treatment of HSV and VZV infections: <strong>acyclovir, valacyclovir, and famciclovir.</strong></li>\n<li>They have similar mechanisms of action and comparable indications for clinical use; all are well tolerated. Acyclovir has been the most extensively studied</li>\n<li>It was licensed first and is the only one of the three that is available for intravenous use in the United States.</li>\n<li>Comparative trials have demonstrated similar efficacies of these three agents for the treatment of HSV, but modest superiority of <strong>famciclovir and valacyclovir </strong>for the treatment of herpes zoster infections.</li>\n<li><strong>Acyclovir</strong>\n<ul>\n<li>First-line drug for HSV and VZV</li>\n<li>Inhibits viral DNA polymerase after phosphorylation by viral thymidine kinase</li>\n</ul>\n</li>\n<li><strong>Valacyclovir</strong>\n<ul>\n<li>Prodrug of acyclovir (better oral bioavailability)</li>\n<li>Converted to acyclovir in the body</li>\n</ul>\n</li>\n<li><strong>Famciclovir</strong>\n<ul>\n<li>Prodrug of penciclovir</li>\n<li>Also used in HSV and VZV infections</li>\n</ul>\n</li>\n</ul>\n<p><strong>Genital Herpes</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509054a7f3a80-2e07-4d5f-b6a7-45337131b286.png\">\n<p><strong>In Pregnancy:</strong> Suppressive therapy should begin at 36 weeks.</p>\n<p>Acyclovir 400 mg TID <strong>or</strong> Valacyclovir 500 mg BID</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acyclovir, penciclovir, famciclovir(Option A):</strong> Penciclovir is <strong>only topical</strong> and not commonly used systemically for genital HSV.</p>\n<p><strong>Valacyclovir, penciclovir, famciclovir(Option C): </strong>Again, <strong>penciclovir</strong> is topical and not a systemic treatment.</p>\n<p><strong>Valacyclovir, famciclovir, lamivudine(Option D): Lamivudine</strong> is <strong>not used for HSV or VZV</strong>; it's a reverse transcriptase inhibitor used in <strong>HIV</strong> and <strong>HBV</strong> treatment.</p>",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">One</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Two</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Three</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Four</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 35-year-old female patient with recurrent herpes labialis came to the OPD for the 5th episode of herpes labialis. She was prescribed acyclovir topical ointment 5 times daily for 4 days. How many phosphorylation steps are required for the activation of acyclovir?</span></p>",
      "unique_key": "DT1176807",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176807,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Acyclovir requires <strong>three </strong>phosphorylation steps for activation.</p>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509052d241e76-03a8-47a3-b7ca-1223cde3f9bf.jpg\">\n<ul>\n<li>Acyclovir is an acyclic guanosine derivative with clinical activity against HSV-1, HSV-2, and VZV, but it is approximately 10 times more potent against HSV-1 and HSV-2 than against VZV. In vitro activity against Epstein-Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus-6 (HHV-6) is present but weaker.</li>\n</ul>\n<p><strong>Acyclovir:</strong></p>\n<p><strong>Acyclovir</strong> is an Acyclic guanosine nucleoside analog, which is an Antiviral drug active against <strong>Herpesviridae</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<p>Acyclovir is selectively activated in infected cells.</p>\n<ul>\n<li><strong>Requires three phosphorylation steps to become active:</strong>\n<ul>\n<li>Step 1: Viral thymidine kinase &rarr; acyclovir monophosphate</li>\n<li>Step 2 &amp; 3: Host cell kinases &rarr; acyclovir diphosphate &rarr; triphosphate</li>\n</ul>\n</li>\n<li><strong>Antiviral effects:</strong>\n<ul>\n<li>Inhibits <strong>viral DNA polymerase</strong> by competing with deoxyGTP</li>\n<li>Causes chain termination after incorporation into viral DNA</li>\n<li>Forms an irreversible complex with viral DNA polymerase and DNA template</li>\n</ul>\n</li>\n</ul>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509050e47b823-1a1c-4405-9063-73a700bd550e.jpg\">\n<p><strong>Pharmacokinetics</strong></p>\n<ul>\n<li>Oral bioavailability: Low (15-20%), unaffected by food</li>\n<li>Topical use: High local concentration, no systemic levels</li>\n<li>IV use: Available and preferred for severe infections</li>\n<li><strong>Excretion: Renal (glomerular filtration + tubular secretion)</strong></li>\n<li><strong>Half-life:</strong>\n<ul>\n<li>~2.5-3 hrs (<strong>normal renal function</strong>)</li>\n<li>~20 hrs (<strong>anuric patients</strong>)</li>\n</ul>\n</li>\n<li>CNS penetration: CSF levels &asymp;20-50% of serum levels</li>\n</ul>\n<p><strong>Clinical Uses:</strong></p>\n<ul>\n<li><strong>HSV infections:</strong>\n<ul>\n<li>Genital/orolabial herpes</li>\n<li>Neonatal HSV (IV)</li>\n<li>Herpes encephalitis (IV)</li>\n</ul>\n</li>\n<li><strong>VZV infections:</strong>\n<ul>\n<li>Chickenpox (if started &lt;24 hrs of rash)</li>\n<li>Herpes zoster (if &lt;72 hrs)</li>\n<li>Immunocompromised VZV &rarr; IV acyclovir</li>\n</ul>\n</li>\n<li><strong>Prophylaxis:</strong>\n<ul>\n<li>In transplant/immunocompromised patients</li>\n<li>In pregnant women with recurrent genital herpes (from 36 weeks of gestation)</li>\n</ul>\n</li>\n</ul>\n<p><strong>Resistance</strong></p>\n<ul>\n<li>Due to Mutations in <strong>viral thymidine kinase (UL23 gene) </strong>and Mutations in <strong>viral DNA polymerase</strong></li>\n<li><strong>Cross-resistance with</strong> Valacyclovir, famciclovir, ganciclovir</li>\n<li><strong>Alternative agents (do not require viral kinase):</strong>\n<ul>\n<li>Foscarnet</li>\n<li>Cidofovir</li>\n<li>Trifluridine</li>\n</ul>\n</li>\n</ul>\n<p><strong>Adverse Effects</strong></p>\n<ul>\n<li><strong>Common (oral):</strong> Nausea, diarrhea, headache</li>\n<li><strong>IV-specific (rare):</strong>\n<ul>\n<li><strong>Nephrotoxicity</strong>: Crystalline nephropathy, interstitial nephritis</li>\n<li><strong>Neurotoxicity</strong>: Tremors, delirium, seizures</li>\n<li><strong>Hematologic:</strong> Reversible neutropenia</li>\n</ul>\n</li>\n<li><strong>High-dose animal toxicity:</strong> Chromosomal damage, testicular atrophy (not seen in long-term human use)</li>\n</ul>",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">2-5 mg/kg</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">5-10 mg/kg</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">10-20 mg/kg</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">30-35 mg/kg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A newborn child is admitted to the NICU for phototherapy for neonatal jaundice. He develops a fever on the 4th day. So, blood culture investigation is done. Blood culture is positive for HSV-1 viral infection. The paediatrician wants to start intravenous acyclovir for treatment. What is the correct dose of acyclovir every 8 hours for the treatment of neonatal HSV infection?</span></p>",
      "unique_key": "DT1176812",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176812,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240325dbf2fad0-0e53-4089-a3cb-e42c86f149cd.jpg\">",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Docosanol</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Foscarnet</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Penciclovir</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Trifluridine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old man is being treated with IV acyclovir for HSV-1 encephalitis, confirmed by CSF culture. He initially improves but develops a fever with chills on day 10. Repeat CSF analysis shows HSV-1 resistant to acyclovir. Which IV drug is preferred for treating acyclovir-resistant HSV infections?</span></p>",
      "unique_key": "DT1176815",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176815,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Preferred IV drug for acyclovir-resistant HSV is Foscarnet</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403253feeab37-9d79-4e67-8212-04e4506a602b.jpg\">\n<p><strong>Resistance to acyclovir: </strong></p>\n<ul>\n<li>Due to Mutations in <strong>viral thymidine kinase (UL23 gene) </strong>and Mutations in <strong>viral DNA polymerase</strong></li>\n<li><strong>Cross-resistance with</strong> Valacyclovir, famciclovir, ganciclovir</li>\n<li><strong>Alternative agents (do not require viral kinase):</strong>\n<ul>\n<li>Foscarnet</li>\n<li>Cidofovir</li>\n<li>Trifluridine</li>\n</ul>\n</li>\n</ul>\n<p><strong>Foscarnet:</strong></p>\n<p>Foscarnet is an Inorganic <strong>pyrophosphate analog</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<ul>\n<li>Directly inhibits<strong> Herpesvirus DNA polymerase, RNA polymerase, and HIV reverse transcriptase</strong></li>\n<li>Binds to the pyrophosphate-binding site of enzymes &rarr; prevents cleavage of pyrophosphate from deoxynucleotide triphosphates &rarr; inhibits DNA synthesis</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905018401a5-72b7-4d97-97c9-b18e5a693de6.jpg\">\n<p><strong>Antiviral Spectrum: </strong>Effective against <strong>HSV</strong>, <strong>VZV, CMV</strong> (including ganciclovir-resistant), <strong>EBV</strong>, <strong>HHV-6</strong>, <strong>HHV-8, HIV-1</strong>, <strong>HIV-2</strong></p>\n<p><strong>Formulation &amp; Administration:</strong></p>\n<ul>\n<li>Only IV (oral use limited by poor bioavailability and GI intolerance)</li>\n<li>Use an infusion pump and saline preloading to reduce nephrotoxicity</li>\n<li>Intravitreally used for CMV retinitis</li>\n</ul>\n<p><strong>Pharmacokinetics</strong></p>\n<ul>\n<li>CSF levels: ~43-67% of plasma</li>\n<li>Plasma half-life: 3-7 hours</li>\n<li>Bone deposition: up to 30% (half-life of months)</li>\n<li>Renal clearance proportional to creatinine clearance &rarr; dose adjustment required</li>\n<li>50% removed via hemodialysis</li>\n</ul>\n<p><strong>Adverse Effects</strong></p>\n<ul>\n<li><strong>Nephrotoxicity</strong>:\n<ul>\n<li>Prevent with <strong>hydration</strong></li>\n<li>Avoid with other nephrotoxic drugs (e.g., amphotericin B, aminoglycosides)</li>\n</ul>\n</li>\n<li><strong>Electrolyte Imbalances</strong>:\n<ul>\n<li>Hypo-/hypercalcemia</li>\n<li>Hypo-/hyperphosphatemia</li>\n<li>Hypokalemia, hypomagnesemia</li>\n</ul>\n</li>\n<li><strong>Genital ulcerations</strong>:\n<ul>\n<li>Due to high urinary concentration of ionized drug</li>\n</ul>\n</li>\n<li><strong>CNS toxicity</strong>:\n<ul>\n<li>Headache, <strong>hallucinations</strong>, <strong>seizures</strong></li>\n<li>Seizure risk &uarr; with <strong>imipenem</strong></li>\n</ul>\n</li>\n<li><strong>Hematologic</strong>:\n<ul>\n<li>Anemia (worse with <strong>zidovudine</strong>)</li>\n<li>&uarr; Liver enzymes</li>\n<li>Fatigue</li>\n</ul>\n</li>\n<li><strong>Carcinogenicity</strong>:\n<ul>\n<li><strong>Chromosomal damage</strong> noted in preclinical studies</li>\n</ul>\n</li>\n</ul>\n<p>S/E of Foscarnet, Cedofovir - Similar to Tenofovir- <strong>Pneumonic Neck Of Femur (NOF)</strong></p>\n<ul>\n<li>Nephrotoxciity</li>\n<li>Osteoporosis</li>\n<li>Fanconi syndrome</li>\n</ul>\n<p>Unique s/e of Foscarnet - Genital ulceration</p>",
      "correct_choice_id": 32,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Idiopathic thrombocytopenic purpura</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Thrombotic thrombocytopenic purpura</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Colon carcinoma</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In patients with AIDS receiving high-dose chronic valacyclovir therapy (8 g/day), which of the following complications has been observed with increased incidence?</span></p>",
      "unique_key": "DT1176819",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176819,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Valacyclovir</strong> is generally well tolerated, although nausea, headache, vomiting, or rash occasionally occur.</li>\n<li>At high doses, confusion, hallucinations, and seizures have been reported.</li>\n<li>AIDS patients who received high-dose valacyclovir chronically (ie, 8 g/d) had an increased incidence of gastrointestinal intolerance as well as <strong>thrombotic thrombocytopenic purpura</strong> and<strong> hemolytic-uremic syndrome</strong>; this dose has also been associated with confusion and hallucinations in transplant patients.</li>\n<li>In a recent study, there was no evidence of increased birth defects in 181 infants who were exposed to valacyclovir during the first trimester.</li>\n</ul>\n<p><strong>Valacyclovir:</strong></p>\n<ul>\n<li>Valacyclovir is the L-valyl ester prodrug of acyclovir.</li>\n<li>After oral administration, it undergoes <strong>first-pass hydrolysis</strong> in the <strong>liver and intestine</strong>, converting rapidly to acyclovir.</li>\n<li>This conversion results in <strong>serum levels 3-5 times higher</strong> than oral acyclovir, <strong>approximating IV acyclovir</strong> levels.</li>\n</ul>\n<p><strong>Clinical Uses:</strong></p>\n<ul>\n<li>Herpes simplex virus (HSV) infections</li>\n<li>Varicella-zoster virus (VZV) infections</li>\n<li>Cytomegalovirus (CMV) prophylaxis in certain settings</li>\n<li><strong>Suppressive therapy</strong> from 36 weeks of gestation in <strong>pregnant women</strong> with <strong>recurrent genital herpes</strong></li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<ul>\n<li>Common: Nausea, headache, vomiting, rash</li>\n<li>High doses (e.g., 8 g/day):\n<ul>\n<li><strong>Neurotoxicity</strong>: Confusion, hallucinations, seizures (especially in transplant patients)</li>\n<li><strong>AIDS patients</strong>: Increased risk of <strong>thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS)</strong> and <strong>GI intolerance</strong></li>\n</ul>\n</li>\n</ul>\n<p><strong><strong>Explanation of Other Options:</strong></strong></p>\n<p><strong>Idiopathic Thrombocytopenic Purpura (Option A): ITP</strong> is an autoimmune condition where the body attacks its platelets, leading to thrombocytopenia. ITP is typically triggered by viral infections, autoimmune diseases, or certain drugs, but <strong>valacyclovir is not among them</strong>.</p>\n<p><strong>Colon carcinoma(Option C): </strong>Valacyclovir is <strong>not mutagenic or carcinogenic</strong>, and there is <strong>no evidence</strong> that it increases the risk of any malignancy.</p>",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Acyclovir</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Valacyclovir</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Ganciclovir</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25-year-old patient came to the OPD with complaints of decreased urine, difficulty in breathing, and bilateral pedal oedema. USG was s/o CRF grade -V. He underwent a series of investigations, and a renal transplant was done. Which anti-viral agent is useful in this pt. for CMV infection prevention?</span></p>",
      "unique_key": "DT1176822",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176822,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403255a9b4cad-5498-4283-9fc2-90feb4168161.jpg\">",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Hepatotoxicity</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">GI intolerance</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Myelosuppression</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Central nervous system toxicity</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is the most common adverse effect associated with systemic (especially intravenous) ganciclovir therapy?</span></p>",
      "unique_key": "DT1176824",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176824,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ol>\n<li><strong>Common Adverse Effect:</strong> Systemic ganciclovir treatment, especially intravenous use, often leads to myelosuppression.</li>\n<li><strong>Myelosuppression:</strong> Myelosuppression entails reduced blood cell production by the bone marrow, causing low white blood cells, red blood cells, and platelets.</li>\n<li><strong>Consequences of Myelosuppression:</strong> This condition increases the risk of infections (due to low white blood cells), causes anemia-related symptoms (due to low red blood cells), and can lead to bleeding tendencies (due to low platelet count).</li>\n</ol>\n<p><strong>Adverse Effects of Ganciclovir:</strong></p>\n<ul>\n<li><strong>Most common</strong>: <strong>Myelosuppression</strong> (dose-limiting)</li>\n<li><strong>Others:</strong>\n<ul>\n<li>GI: Nausea, diarrhea<strong>(Option B ruled out)</strong></li>\n<li>CNS: Headache, insomnia, confusion, seizures, psychiatric symptoms <strong>(Option D ruled out)</strong></li>\n<li>Skin: Rash</li>\n<li>Liver: Rare <strong>hepatotoxicity(Option A ruled out)</strong></li>\n<li>Eye (intravitreal use): Vitreous hemorrhage, retinal detachment</li>\n</ul>\n</li>\n<li><strong>Long-term risks</strong> (in animals):\n<ul>\n<li><strong>Carcinogenic</strong>, <strong>embryotoxic</strong>, and <strong>aspermatogenesis</strong></li>\n<li><strong>Mutagenic</strong> in mammalian cells (clinical significance unknown)</li>\n</ul>\n</li>\n</ul>",
      "correct_choice_id": 63,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">NRTIs</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">NNRTIs</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">CCR4 receptor antagonist</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Fusion inhibitors</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not an ART agent?</span></p>",
      "unique_key": "DT1176835",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176835,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>The CCR4 receptor antagonist </strong>is not used in HIV therapy. <strong>Maraviroc, a CCR5 receptor antagonis</strong>t, is used in ART. CCR4 is not a recognized target in HIV treatment.</p>\n<p><strong>Antiretroviral Therapy (ART) agents:</strong></p>\n<ol>\n<li><strong>NRTIs (Nucleoside/Nucleotide Reverse Transcriptase Inhibitors)</strong>\n<ul>\n<li><strong>Mechanism: </strong>Act as faulty DNA building blocks, inhibiting reverse transcription.</li>\n<li><strong>Examples: </strong>Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TDF, TAF), Emtricitabine (FTC), Abacavir (ABC), Stavudine (d4T), Didanosine (ddI)</li>\n</ul>\n</li>\n<li><strong>NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)</strong>\n<ul>\n<li><strong>Mechanism: </strong>Bind to and inhibit reverse transcriptase at a different site than NRTIs.</li>\n<li><strong>Examples: </strong>Efavirenz, Nevirapine, Etravirine, Rilpivirine, Doravirine</li>\n</ul>\n</li>\n<li><strong>PIs (Protease Inhibitors)</strong>\n<ul>\n<li><strong>Mechanism: </strong>Inhibits the HIV protease enzyme, preventing viral maturation.</li>\n<li><strong>Examples: </strong>Lopinavir, Ritonavir (used mainly as a booster), Atazanavir, Darunavir, Indinavir, Saquinavir</li>\n</ul>\n</li>\n<li><strong>INSTIs (Integrase Strand Transfer Inhibitors)</strong>\n<ul>\n<li><strong>Mechanism: </strong>Inhibits the HIV integrase enzyme, blocking the integration of viral DNA into host DNA.</li>\n<li><strong>Examples: </strong>Dolutegravir, Raltegravir, Bictegravir, Elvitegravir</li>\n</ul>\n</li>\n<li><strong>Entry and Fusion Inhibitors</strong>\n<ul>\n<li>Fusion Inhibitors: Enfuvirtide (T-20) blocks the fusion of HIV with the host cell.</li>\n<li>CCR5 Receptor Antagonists (Entry Inhibitors): Maraviroc blocks the CCR5 co-receptor (not CCR4).</li>\n</ul>\n</li>\n<li><strong>Post-Attachment Inhibitor: </strong>Ibalizumab, a monoclonal antibody used for multidrug-resistant HIV.</li>\n<li><strong>CXCR4 inhibitor: </strong>Plerixafor</li>\n</ol>",
      "correct_choice_id": 73,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Abacavir is an NNRTI agent</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Patient taking abacavir advised to take alcohol along with it</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Testing to rule out the HLA-B5701 allele is recommended before initiating therapy</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is true for Abacavir?</span></p>",
      "unique_key": "DT1176836",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176836,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong>:</p>\n<p><strong>HLA-B5701 testing is mandatory</strong> before starting therapy. If a patient is positive for this allele, <strong>abacavir is contraindicated</strong>. This test is essential to reduce the risk of <strong>abacavir hypersensitivity reaction</strong>, which can be severe and life-threatening.</p>\n<p><strong>Abacavir: </strong></p>\n<p><strong>Drug Class:</strong></p>\n<ul>\n<li>Nucleoside Reverse Transcriptase Inhibitor (NRTI)<strong>(Option A ruled out)</strong></li>\n<li>Guanosine analog</li>\n</ul>\n<p><strong>Pharmacokinetics:</strong></p>\n<ul>\n<li><strong>Oral bioavailability:</strong> ~83% (not affected by food)</li>\n<li><strong>Half-life (serum):</strong> ~1.5 hours</li>\n<li><strong>Metabolism:</strong>\n<ul>\n<li>Hepatic: via <strong>glucuronidation</strong> and <strong>carboxylation</strong></li>\n<li>Also metabolized by <strong>alcohol dehydrogenase</strong> &rarr; alcohol increases abacavir serum levels</li>\n</ul>\n</li>\n<li><strong>CSF penetration:</strong> ~1/3 of plasma levels</li>\n</ul>\n<p><strong>Drug Interactions:</strong></p>\n<ul>\n<li><strong>Increased levels with alcohol</strong> (ethanol competes for metabolism)<strong>(Option B ruled out)</strong></li>\n<li>Decreased levels when co-administered with:\n<ul>\n<li>Atazanavir</li>\n<li>Lopinavir</li>\n</ul>\n</li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<h4><strong>Hypersensitivity Reaction (HSR):</strong></h4>\n<ul>\n<li>Seen in <strong>~8%</strong> of patients</li>\n<li>May be <strong>fatal</strong></li>\n<li>More severe with <strong>once-daily dosing</strong></li>\n<li><strong>Onset:</strong> Usually within the <strong>first 6 weeks</strong></li>\n<li><strong>Symptoms:</strong>\n<ul>\n<li>Fever, fatigue, nausea, vomiting, diarrhea</li>\n<li>Abdominal pain, rash (~50%), dyspnea, cough</li>\n<li>Elevated <strong>ALT, CK</strong> levels</li>\n</ul>\n</li>\n<li><strong>Management:</strong>\n<ul>\n<li><strong>Do not rechallenge</strong></li>\n<li><strong>HLA-B*5701 testing is mandatory</strong> before starting therapy\n<ul>\n<li>Positive predictive value: ~50%</li>\n<li><strong>Negative predictive value: ~100%</strong></li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<p><strong>Other Adverse Effects:</strong></p>\n<ul>\n<li>Rash (~5%)</li>\n<li>Headache, fatigue, dyspnea</li>\n<li><strong>Pancreatitis</strong> (less common)</li>\n<li><strong>Potential CV risk:</strong> Avoid in patients with <strong>coronary artery disease</strong></li>\n<li><strong>Mitochondrial toxicity &amp; lipid disorders:</strong> Less common than with other NRTIs</li>\n</ul>\n<p><strong>Use in Pregnancy: Recommended</strong> for use in pregnant women as part of a combination ART</p>",
      "correct_choice_id": 83,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine + Lamivudine + Nevirapine</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Tenofovir + Emtricitabine + Efavirenz</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Tenofovir Disoproxil Fumarate + Lamivudine + Dolutegravir</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Abacavir + Lamivudine + Rilpivirine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 35-year-old male patient with HIV presents with chronic diarrhea and is started on ART. While collecting a blood sample, an intern sustains a needle-stick injury. He reports immediately to the ART center for post-exposure prophylaxis (PEP). Which of the following drug combinations is recommended for PEP?</span></p>",
      "unique_key": "DT1176838",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176838,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>According to <strong>NACO 2023 guidelines</strong> for <strong>HIV PEP</strong>, the recommended regimen is:</p>\n<ul>\n<li><strong>Tenofovir Disoproxil Fumarate (TDF)</strong> 300 mg</li>\n<li><strong>Lamivudine (3TC)</strong> 300 mg</li>\n<li><strong>Dolutegravir (DTG)</strong> 50 mg once daily</li>\n<li><strong>Duration:</strong> 28 days</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905d55550e6-a358-41e8-9bfd-1f6a3911eb46.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Zidovudine + Lamivudine + Nevirapine</strong>:</p>\n<p>Outdated. Nevirapine is <strong>not recommended</strong> due to <strong>hepatotoxicity risk</strong> and poor safety in PEP.</p>\n<p><strong>Tenofovir + Emtricitabine + Efavirenz</strong>:</p>\n<p>Previously used, but <strong>Efavirenz</strong> has <strong>CNS side effects</strong>, and <strong>DTG is now preferred</strong> for its high potency and tolerability.</p>\n<p><strong>Abacavir + Lamivudine + Rilpivirine</strong>:</p>\n<p>Not recommended for PEP. <strong>Abacavir requires HLA-B*5701 testing</strong>, and <strong>Rilpivirine</strong> has restrictions like food requirements and can't be used with high viral loads.</p>",
      "correct_choice_id": 93,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Tenofovir</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Emtricitabine</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Lamivudine</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">All the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs can be used as pre-exposure prophylaxis of HIV?</span></p>",
      "unique_key": "DT1176839",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176839,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Pre-Exposure Prophylaxis (PrEP) for HIV:</strong></p>\n<p>Pre-exposure prophylaxis (PrEP) is the use of antiretroviral drugs by HIV-negative individuals at high risk of HIV exposure to prevent infection.</p>\n<p><strong>Recommended PrEP Regimens (as per NACO &amp; WHO 2024 guidelines)</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509054dd9ee37-c379-46bf-81eb-a7c694327194.png\">\n<p><strong>Indications for PrEP</strong></p>\n<ul>\n<li>Serodiscordant couples (one partner HIV-positive)</li>\n<li>MSM (men who have sex with men)</li>\n<li>Transgender individuals are at risk</li>\n<li>Sex workers</li>\n<li>IV drug users sharing needles</li>\n<li>Individuals with multiple sexual partners who do not use condoms</li>\n</ul>",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Nevirapine</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Tenofovir</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Sofosbuvir</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which drug is used as a single dose for the prevention of HIV from mother to neonate at the onset of labour?</span></p>",
      "unique_key": "DT1176841",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176841,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>A single dose of <strong>nevirapine</strong> (200 mg) is effective in the prevention of transmission of HIV from mother to newborn when administered to women <strong>at the onset of labor </strong>and followed by a <strong>2 mg/kg oral dose to the neonate within 3 days after delivery.</strong></li>\n<li>There is no evidence of human teratogenicity. However, resistance has been documented after this single dose.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090591de0329-150c-4c28-a726-fabd86f1c52b.jpg\">\n<p><strong>Infant Prophylaxis (Post-Delivery)</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905b38ac5e9-3219-44c5-a039-aecd05f749b3.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Zidovudine(Option B): </strong>Used in <strong>combination regimens</strong> for PMTCT but <strong>not as a single dose</strong> at labor onset.</p>\n<p><strong>Tenofovir(Option C): </strong>Part of <strong>combination ART regimens</strong> during pregnancy, not used as a single dose at labor onset.</p>\n<p><strong>Sofosbuvir(Option D): </strong>An <strong>antiviral for Hepatitis C</strong>, <strong>not used in HIV prophylaxis</strong>.</p>",
      "correct_choice_id": 111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Sentence 1 and 2 both are True, and 2 is the correct reason for 1</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Sentences 1 and 2 both are True, but 2 is not the correct reason for 1</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Sentence 1 is True, but Sentence 2 is False</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Sentences 1 and 2 are both False</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">1. Lopinavir is currently formulated only in combination with ritonavir<br>2. It inhibits CYP2A-mediated metabolism of lopinavir</span></p>",
      "unique_key": "DT1176842",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176842,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>Lopinavir and ritonavir are Protease Inhibitors.</li>\n<li>Lopinavir is currently formulated only in combination with ritonavir, which inhibits the <strong>CYP3A-mediated metabolism</strong> of lopinavir, thereby resulting in increased exposure to lopinavir.</li>\n<li>In addition to improved patient compliance due to reduced pill burden, lopinavir/ritonavir is generally well tolerated.</li>\n</ul>\n<p><strong>Protease Inhibitors:</strong></p>\n<p><strong>Mechanism of Action:</strong></p>\n<p>PIs inhibit the HIV protease enzyme, which is essential for cleaving the Gag-Pol polyprotein during the final stages of the HIV life cycle.</p>\n<p><strong>Pharmacokinetics &amp; Boosting:</strong></p>\n<ul>\n<li><strong>PIs are often co-administered</strong> with:\n<ul>\n<li><strong>Ritonavir</strong> (low-dose: 100-200 mg) or</li>\n<li><strong>Cobicistat</strong> (has no antiviral activity)</li>\n</ul>\n</li>\n<li><strong>Purpose of Boosting</strong>:<br /> Inhibits <strong>CYP3A4</strong>, increasing the serum levels and half-life of the primary PI.<br /> Improves efficacy and raises the <strong>genetic barrier to resistance</strong>.</li>\n</ul>\n<p><strong>Adverse Effects of Protease Inhibitors (PIs)</strong></p>\n<ul>\n<li><strong>Gastrointestinal:</strong>\n<ul>\n<li>Nausea</li>\n<li>Vomiting</li>\n<li>Diarrhea (often dose-limiting)</li>\n</ul>\n</li>\n<li><strong>Metabolic:</strong>\n<ul>\n<li>Hyperglycemia</li>\n<li>Hyperlipidemia</li>\n<li>Insulin resistance</li>\n</ul>\n</li>\n<li><strong>Morphologic (Lipodystrophy Syndrome):</strong>\n<ul>\n<li>Central obesity</li>\n<li>Buffalo hump (dorsocervical fat pad)</li>\n<li>Facial and peripheral fat wasting (lipoatrophy)</li>\n<li>Breast enlargement</li>\n<li>Cushingoid appearance</li>\n</ul>\n</li>\n<li><strong>Cardiovascular:</strong>\n<ul>\n<li>PR interval prolongation</li>\n<li>QT interval prolongation</li>\n<li>&uarr; Cardiovascular disease risk (notably with abacavir and lopinavir/ritonavir)</li>\n</ul>\n</li>\n<li><strong>Hepatic:</strong>\n<ul>\n<li>Drug-induced hepatitis</li>\n<li>Severe hepatotoxicity (especially with tipranavir/ritonavir)</li>\n<li>Unconjugated hyperbilirubinemia (especially with atazanavir)</li>\n</ul>\n</li>\n<li><strong>Skeletal:</strong>\n<ul>\n<li>Potential bone loss and osteoporosis (long-term use; under investigation)</li>\n</ul>\n</li>\n<li><strong>Hematologic:</strong>\n<ul>\n<li>Increased spontaneous bleeding in patients with hemophilia A or B</li>\n<li>Risk of intracranial hemorrhage (noted with tipranavir/ritonavir)</li>\n</ul>\n</li>\n<li><strong>Allergic Reactions:</strong>\n<ul>\n<li><strong>Darunavir</strong> is a sulfonamide &rarr; Use with caution in patients with sulfa allergy</li>\n</ul>\n</li>\n</ul>",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">1-a, 2-c, 3-d, 4-b</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">1-b, 2-a, 3-d, 4-c</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">1-c, 2-a, 3-d, 4-d</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">1-d, 2-b, 3-a, 4-c</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following for ART agents.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024032259b83918-43da-42cc-913c-491a288ea328.jpg\"></span></p>",
      "unique_key": "DT1176843",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176843,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509056ba93ad3-a979-4e80-95a9-6f61c640bfe3.png\"><br>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403225c2eaa7e-0b82-4c39-8eb1-18373730f4bd.jpg\">",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Interferon alfa-2b</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Lamivudine</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Tenofovir</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not approved for HBV treatment?</span></p>",
      "unique_key": "DT1176845",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176845,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>HBV infection in the United States: five oral nucleoside/nucleotide analogues (<strong>lamivudine</strong>, adefovir dipivoxil, <strong>tenofovir</strong>, entecavir, telbivudine) and two injectable interferon drugs (<strong>interferon alfa-2b</strong>, pegylated interferon alfa-2a)</li>\n</ul>\n<p><strong>First-Line Antiviral Drugs for HBV</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090502bf14b9-4b45-41e9-b470-e619127b2e4c.png\">\n<p><strong>Other Drugs:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905a1399877-da9c-45ad-8d93-8c098df04057.png\">",
      "correct_choice_id": 144,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Tenofovir</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Zidovudine</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Sofosbuvir</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which drug is useful against HCV?</span></p>",
      "unique_key": "DT1176848",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176848,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Sofosbuvir( Nucleotide Analog for HCV):</strong></p>\n<p><strong>Mechanism of Action: </strong></p>\n<ul>\n<li><strong>Prodrug</strong> converted intracellularly to active <strong>uridine analog triphosphate</strong> (GS-461203).</li>\n<li>Incorporated into viral RNA by <strong>NS5B RNA-dependent RNA polymerase</strong>.</li>\n<li>Causes <strong>chain termination</strong>, halting HCV replication.</li>\n</ul>\n<p><strong>Indications &amp; Combinations</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905a4e38394-d7dc-457c-9140-3aef5d9208d9.png\">\n<p><strong>Pharmacokinetics</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905295e8ff8-70f3-4c2b-8b16-0b8ba3958488.png\">\n<p><strong>Adverse Effects</strong></p>\n<ul>\n<li><strong>Common</strong> (in combination therapy): Fatigue, headache, asthenia</li>\n<li><strong>Rare but notable</strong>: <strong>Symptomatic bradycardia</strong> (especially with <strong>amiodarone</strong>, &beta;-blockers, or advanced liver disease), <strong>Severe cutaneous reactions</strong></li>\n</ul>\n<p><strong><strong>Treatment of Hepatitis C:</strong></strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090530520de8-6071-4c24-89a3-e78a199a787f.png\">\n<p><strong>DAAs target proteins essential for viral replication:</strong></p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025090589a42f81-7e9e-43bf-9d1a-fb8fa5de3b33.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Tenofovir(Option A): </strong>Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI) primarily used for HIV and HBV infections. It has no significant role in treating HCV. While some studies explored its use in coinfection settings, Tenofovir does not directly act on the HCV replication machinery.</p>\n<p><strong>Zidovudine(Option B):</strong> Zidovudine is also an NRTI used in the management of HIV. It has no antiviral activity against HCV and is not part of any HCV treatment regimen.</p>",
      "correct_choice_id": 153,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Oseltamivir</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Fevipiravir</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Remdesivir</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">All of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old woman presents with the sudden onset of high-grade fever, dry cough, sore throat, and myalgia during the peak flu season. She reports recent contact with a co-worker diagnosed with H1N1 (Swine flu). What is the most commonly used antiviral drug for the treatment of this condition?</span></p>",
      "unique_key": "DT1176849",
      "question_audio": null,
      "question_video": null,
      "map_id": 1176849,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li>The neuraminidase inhibitors<strong> oseltamivir and zanamivir</strong>, analogues of sialic acid, interfere with the release of progeny <strong>influenza virus</strong> from infected host cells, thus halting the spread of infection within the respiratory tract.</li>\n<li>These agents competitively and reversibly interact with the active enzyme site to inhibit viral neuraminidase activity at low nanomolar concentrations.</li>\n<li>Inhibition of viral neuraminidase results in clumping of newly released influenza virions with each other and the membrane of the infected cell.</li>\n</ul>\n<p><strong>Oseltamivir:</strong></p>\n<p>Class of<strong> Neuraminidase inhibitors </strong>(along with Zanamivir)<strong>. </strong>Analog of sialic acid</p>\n<h4><strong>Mechanism of Action:</strong></h4>\n<ul>\n<li>Inhibits viral neuraminidase of <strong>Influenza A &amp; B</strong></li>\n<li>Prevents the release of progeny virions from infected cells</li>\n<li>Causes clumping of virions &rarr; reduces the spread of infection</li>\n</ul>\n<p><strong>Clinical Use:</strong></p>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509052ccf6fc8-ac46-4eee-9239-004ea9297e7e.png\">\n<p><strong>Pharmacokinetics:</strong></p>\n<ul>\n<li><strong>Prodrug</strong> (activated by hepatic esterases)</li>\n<li><strong>Oral bioavailability:</strong> ~80%</li>\n<li><strong>Distribution:</strong> Plasma, sinus, middle ear fluid</li>\n<li><strong>Half-life:</strong> 6-10 hours</li>\n<li><strong>Excretion:</strong> Renal (glomerular filtration + tubular secretion)</li>\n<li><strong>Drug interaction:</strong> Probenecid &darr; reduces renal clearance by ~50%</li>\n</ul>\n<p><strong>Adverse Effects:</strong></p>\n<ul>\n<li><strong>Common: </strong>Nausea, vomiting, Headache, fatigue, diarrhea (more common in prophylaxis)</li>\n<li><strong>Rare: </strong>Rash, <strong>Neuropsychiatric events</strong> (delirium, self-injury), especially in adolescents (notably in Japan)</li>\n<li><strong>Caution: Renal insufficiency:</strong> Dose adjustment required</li>\n</ul>\n<p><strong>Classification of Anti-Influenza Drugs</strong></p>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250905a2cf2a6e-9d25-4a79-bce7-5ac8caadfe99.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Favipiravir(Option B)</strong>: Used for severe or refractory viral infections, <strong>not first-line</strong> for seasonal influenza.</p>\n<p><strong>Remdesivir(Option C)</strong>: Approved for <strong>COVID-19</strong>, <strong>not used for influenza</strong>.</p>",
      "correct_choice_id": 161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}